ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram
Selskabsmeddelelse
for ROCKWOOL A/S
Meddelelse nr. 20 – 2024
til Nasdaq Copenhagen
1. maj 2024
ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram
Som meddelt i selskabsmeddelelse nr. 02/2024 har ROCKWOOL A/S iværksat et aktietilbagekøbsprogram, som løber i perioden fra og med 8. februar 2024 og til og med den 7. februar 2025. I denne periode vil Selskabet købe egne aktier for op til maksimalt 160 mio. euro.
Tilbagekøbsprogrammet gennemføres i henhold til EU-Kommissionens forordning nr. 596/2014 af 16. april 2014 og EU-Kommissionens delegerede forordning nr. 2016/1052 af 8. marts 2016, der tilsammen udgør ”Safe harbour” reguleringen.
I perioden 24. – 30. april 2024 er foretaget følgende køb:
| Dato | Antal B-aktier | Gennemsnitlig købspris B-aktier (DKK) | Samlet beløb B-aktier (DKK) |
| [I alt, seneste meddelelse] | 148.300 | 326.625.228 | |
| 24. april 2024 | 2.000 | 2.308,27 | 4.616.540 |
| 25. april 2024 | 3.500 | 2.260,12 | 7.910.420 |
| 26. april 2024 | 1.700 | 2.322,07 | 3.947.519 |
| 29. april 2024 | 1.700 | 2.322,38 | 3.948.046 |
| 30. april 2024 | 1.600 | 2.304,17 | 3.686.672 |
| Akkumuleret under programmet (B-aktier) | 158.800 | 350.734.425 |
ROCKWOOL A/S ejer herefter 219.088 B-aktier svarende til 1,01 % af selskabets samlede aktiekapital.
Separat oversigt med transaktionsdata for perioden 24. – 30. april 2024 vedlægges denne meddelelse.
Yderligere information:
Kim Junge Andersen
Senior Vice President, CFO
ROCKWOOL A/S
+45 46 55 80 15
Vedhæftede filer
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
LambdaTest Announces Seamless Integration with PractiTest for Enhanced Testing Capabilities21.5.2024 18:00:00 CEST | Press release
LambdaTest's integration with PractiTest enhances testing capabilities, streamlining bug tracking and management for efficient software delivery. San Francisco, May 21, 2024 (GLOBE NEWSWIRE) -- LambdaTest, a leading test orchestration and execution platform, is excited to announce its integration with PractiTest, a leading provider of quality assurance and test management platform. This collaboration aims to transform the testing landscape by equipping organizations with advanced bug-tracking and management capabilities. PractiTest stands out in the landscape of QA and test management solutions, offering users exceptional control and visibility over their testing processes. Through seamless integration with LambdaTest, PractiTest enables organizations to streamline their testing workflows and enhance communication among stakeholders, ensuring the seamless delivery of high-quality software products. The integration with PractiTest brings forth several key benefits for LambdaTest users.
AKVA group ASA: Status buyback of own shares21.5.2024 17:57:28 CEST | Press release
As announced on 22 March 2024 AKVA group ASA ("AKVA group" or the "Company") has initiated repurchase of up to 200,000 of the company's own shares to be used in its share programme for employees. From 14 May through 21 May the company bought 10 596 shares at an weighted average price of NOK 65,6770. See the attached documents for detailed information about the transactions made. The company has bought a total of 79 088 shares at an weighted average price of NOK 67,6067 since 22 March. After these transactions, the company owns 237 804 treasury shares. This information is made public by the Company pursuant to the EU Market Abuse Regulation article 5, as supplemented by Commission Delegated Regulation (EU) 2016/1052 and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Dated: 21 May 2024 AKVA group ASA Web: www.akvagroup.com CONTACTS: Knut Nesse Chief Executive OfficerPhone:+47 51 77 85 00Mobile:+47 91 37 62 20E-mail:knesse@akvagrou
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders21.5.2024 17:30:14 CEST | Press release
Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved. The shareholders approved the proposals to reappoint Ms. Barbara Yanni (agenda item 4.a) and Mr. Mark Pykett (agenda item 4.b), upon binding recommendation of the Board of Directors, as Non-Executive Directors for a period of four years. In addition, the proposals for the adoption of the updated Remuneration Policy for members of the Board of Directors (agenda item 3), the authorization for the Board of Directors to issue shares and/or options (agenda item 5) and the authorization for the Board of Directors to repurchase shares (agenda item 6) were approved by the shareholders. A recording of the webcast, presentation slides from today’s AGM, and more details regarding agenda items are available on the Company’s website in the Investor Relations section. About P
Genmab Completes Acquisition of ProfoundBio21.5.2024 17:06:00 CEST | Press release
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cashAcquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate technology platforms COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers in an all-cash transaction of USD 1.8 billion (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses). With the completion of this strategic transaction, we are excited to welcome our new colleagues and their expertise in developing next-generation antibody-drug conjugates to our exceptionally talented R&D team,” said Jan van de Winkel, Ph.D., President and Chief Executive Officer of Genma
Director/PDMR Shareholding21.5.2024 17:03:14 CEST | Press release
Toronto, Ontario, May 21, 2024 (GLOBE NEWSWIRE) -- (“Amaroq Minerals” or the “Company”) Director/PDMR Shareholding - Notification of Transactions of Directors/Persons Discharging Managerial Responsibilities (PDMRs) TORONTO, ONTARIO – May 21, 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ) announces that on May 17, 2024, it was informed that Livermore Strategic Opportunities LP in which David Neuhauser, Non-Executive Director of Amaroq Minerals, is Managing Director, acquired a total of 19,500 common shares of no par value in the Company. This brings David Neuhauser's indirect total holding to 14,520,624 shares, representing 4.45% of the Company's capital. DEALING NOTIFICATION FORM FOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS 1.Details of the person discharging managerial responsibilities/person closely associated a)Name:Livermore Strategic Opportunities LP, David Neuhauser2. Reason for the notificationa)Position/status:Non-